Does glioblastoma radiotherapy need to be synchronized with temozolomide?

Radiotherapy for glioblastoma is generally recommended to be administered concurrently with temozolomide, based on current clinical practice and recommendations from multiple authoritative guidelines.

Concurrent chemoradiotherapy can combine the advantages of radiotherapy and chemotherapy and work together on tumor cells through different mechanisms to enhance the therapeutic effect. Radiotherapy directly kills tumor cells through high-energy rays, while temozolomide inhibits the growth of tumor cells by interfering with their DNA replication. The combination of the two can kill tumor cells more effectively and reduce the risk of recurrence.

For highly malignant tumors such as glioblastoma, simple surgical resection is often difficult to completely remove tumor cells. Concurrent chemoradiotherapy can improve local control rate and reduce tumor recurrence at the primary site.

Multiple clinical studies have shown that concurrent chemoradiotherapy can significantly prolong the survival of patients with glioblastoma. Through comprehensive treatment methods, tumor progression can be better controlled and patients' quality of life improved.

Temozolomide is an oral chemotherapy drug with the advantages of convenient administration and good patient tolerance. During concurrent chemoradiotherapy, patients can receive chemotherapy through oral medications, avoiding the pain and inconvenience caused by intravenous injections. Temozolomide can penetrate the blood-brain barrier and enter the central nervous system to exert anti-tumor effects. This is particularly important for the treatment of intracranial tumors such as glioblastoma, ensuring that the drug acts directly on the tumor site. During concurrent chemoradiotherapy, doctors can flexibly adjust the dose of temozolomide based on the patient's specific conditions and tolerance. This helps to minimize adverse drug reactions while ensuring therapeutic efficacy.